| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-07-22 | Amag Pharmaceuticals (USA - MA) Velo Bio (USA) | Digoxin immune fab (DIF) | severe preeclampsia in pregnant women | product acquisition |
Women health | Product acquisition |
| 2015-07-22 | Auspherix (Australia) Auspherix Limited (UK) | nomination |
Infectious diseases | Nomination | ||
| 2015-07-21 | Intercept Pharmaceuticals (USA - NY) | nomination |
Liver diseases - Hepatic diseases | Nomination | ||
| 2015-07-21 | Argos Therapeutics (USA - NC) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-07-21 | Ares | nomination |
Allergic diseases | Nomination | ||
| 2015-07-21 | Ares Allergy (UK) | nomination |
Allergic diseases | Nomination | ||
| 2015-07-21 | Axxam (Italy) Bayer (Germany) | services contract |
Technology - Services | Services contract | ||
| 2015-07-21 | Sygnis (Germany) Thermo Fisher Scientific (USA - MA) | Double Switch technology | licensing |
Technology - Services | Licensing agreement | |
| 2015-07-21 | Alimera Sciences (USA - GA) Knight Therapeutics (Canada) | Iluvien® | chronic diabetic macular edema (DME) | distribution | Ophtalmological diseases | Distribution agreement |
| 2015-07-20 | Ultragenyx Pharmaceutical (USA - CA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-07-20 | Telesta Therapeutics (Canada) BL&H Co (South Korea) | MCNA (Mycobacterium phlei Cell wall-Nucleic Acid complex) | high risk non-muscle invasive bladder cancer (NMIBC) | licensing supply distribution |
Cancer - Oncology | Licensing agreement |
| 2015-07-20 | Atyr Pharma (USA - CA) | nomination |
Rare diseases | Nomination | ||
| 2015-07-16 | Swedish Orphan Biovitrum (Sobi) (Sweden) BiogenIdec (USA - MA) | long-lasting rFVIIIFc (Elocta®) and rFIXFc (Alprolix™ - eftrenonacog alfa) hemophilia programs | hemophilia A, hemophilia B | development |
Hematological diseases - Genetic diseases - Rare diseases | Exercise of an option agreement |
| 2015-07-16 | Oncodesign (France) | nomination |
Cancer - Oncology - Technology - Services | Nomination | ||
| 2015-07-16 | AstraZeneca (UK) Kyowa Hakko Kirin (Japan) | benralizumab | asthma, chronic obstructive pulmonary disease (COPD) | commercialisation |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Commercialisation agreement |
| 2015-07-16 | Uniqure (The Netherlands) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-07-15 | Fate Therapeutics (USA - CA) | nomination |
Cancer - Oncology - Autoimmune diseases - Hematological diseases | Nomination | ||
| 2015-07-15 | CytoDyn (Canada) | nomination |
Infectious diseases | Nomination | ||
| 2015-07-15 | Galapagos (Belgium) HUB foundation for use of Organoid Technology (The Netherlands ) | organoid technology | cystic fibrosis, inflammatory bowel disease | licensing |
Inflammatory diseases - Gastrointestinal diseases - Rare diseases - Genetic diseases | Licensing agreement |
| 2015-07-15 | Erytech Pharma (France) | nomination |
Nomination |
